UChicago Medicine Comprehensive Cancer Center

Clonal hematopoiesis of indeterminate potential (CHIP), is the presence of acquired mutations in blood cells of an individual in the absence of an overt blood cancer. It is not a condition that you are born with, but rather something that can happen later in life as you age, receive chemotherapy or radiation therapy for cancer, or due to other factors such as inflammation or toxic exposures.

Having CHIP can put you at risk for a range of medical conditions, including an increased risk for developing blood cancers, cardiovascular diseases such as stroke and heart attacks, gastrointestinal diseases or autoimmune diseases.

CHIP is common and more than 10% of adults age 60 and above have it. This frequency is higher for cancer survivors and individuals with significant cardiovascular disease history.

While screening for CHIP is not currently offered in most hospitals, the University of Chicago Medicine has the means to test for it. Additionally, our physician-scientists actively engage in research to advance the understanding of this condition and better help the individuals who live with it.

At the UChicago Medicine CHIP Clinic, our experts will assess each patient on an individual basis, and create a treatment plan for coordinated, ongoing care that may include other specialists.


Who Treats CHIP?

While the CHIP Clinic is part of the UChicago Medicine Comprehensive Cancer Center, our CHIP team works closely with a variety of UChicago Medicine specialists. In addition to monitoring for blood cancers, most CHIP patients will also be referred to our cardio-oncology team for cardiovascular health monitoring.